We therefore sequenced these MAP2K1 loci (together with additional mutation hotspots in 34 other genes) in a series of plasma DNA samples collected from 22 colorectal cancer patients who acquired resistance to treatment with EGFR therapies (either Cetuximab or Panitumumab) after an initial response. Here, MAP2K1 is linked to colorectal cancer.